Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017
Executive Summary
Zarxio and Basaglar will be the beneficiaries of the cost-cutting move, although how much it will help the follow-on products remains unclear.
You may also be interested in...
A Look At Payers' Early Game Plans For Driving Biosimilar Use
Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.
A Look At Payers' Early Game Plans For Driving Biosimilar Use
Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.
Biosimilar Prescribing Decisions May Depend Upon Disease State
Express Scripts’ Eichholz says clinicians may be less inclined to use a biosimilar in ‘life or death’ oncology indications compared to inflammatory diseases.